The World Health Organization has deemed obesity to be a global epidemic which is now spreading beyond developed countries. It affects 650 million adults worldwide and seriously impacts the health of those afflicted with the condition.
It is a multi-factorial metabolic disorder which leads to an accumulation of fat by the adipocytes. Treatment of obesity mainly consists of reducing overweight by making dietary and lifestyle changes, and may even involve surgery.
Insulin resistance, extremely common among obese patients, is a major factor in developing obesity. Recent scientific literature has also established a close link between obesity and the intestinal microbiota, thus imbalances in the intestinal microbiota have become a promising target for new prevention strategies.
Sources: WHO; CANI P. et al, Diabetes, obesity and gut microbiota, Best Practice & Research Clinical Gastroenterology, 2013.Learn more
billion adults worldwide are overweight according to WHO estimates.
Source: WHO, 2018
times more risk of developing a coronary disease in women suffering from obesity compared to the average (1.7 in men).
Source: HAS, 2011
LpD64 is a patented extract derived from a combination of 5 plants. It is the result of in-depth research and development lasting several years.
LpD64 modulates the intestinal microbiota: it was developed to target the energy metabolism and regulates the intestinal microbiota imbalances associated with developing obesity.
LpD64 could become a flagship healthcare product as part of the support strategies for overweight and obese patients.
LpD64 shown its capacity to regulate the intestinal microbiota, by acting on the bacterial targets involved in developing obesity in clinically relevant in vivo models.
This significant impact of LpD64 on these dysbioses is consistent with the effects measured on the energy metabolism.
LpD64 has a highly significant effect on the energy metabolism in preclinical models for overweight and obesity:
The controlled, open label Phase I/II study, was conducted on 20 obese patients and was completed in September 2018. It validated the safety and tolerance of LpD64 and provided the first proof of concept in humans.
In line with the preclinical studies, the results demonstrated a significant effect on the energy metabolism:
Following the success of the Phase I/II study completed in 2018, LpD64 is ready to enter Phase II of clinical development. This development stage precedes the submission of an application for a health claim recognized by regulatory health authorities.
The pending Phase II trials should prove the efficacy of LpD64 on a larger population of obese patients.
The protection strategy for LpD64 is global: patent applications have been filed for the product in over 60 countries, including American, Canadian and European territories.